Rudolf Hanko will step down as Chief Executive Officer of Siegfried Group on 31 December 2018. The Board of Directors appointed Wolfgang Wienand as new CEO of Siegfried Group with effect from 1 January 2019 The Board has decided to propose the election of Rudolf Hanko as a member of Siegfried Holding AG’s Board of Directors on the occasion of the next Annual General Meeting in spring 2019.
Rudolf Hanko (born 1955) assumed operational responsibility for Siegfried as CEO in 2009. Andreas Casutt, Chairman of Siegfried: «Rudolf Hanko has had a significant effect on our company in the past nine years, and he played a decisive role in Siegfried’s continuing success. His term of office is characterized by the development of annual sales from 260 to over 700 million Swiss francs and, especially, by the targeted expansion of our production sites and the consistent orientation of our company toward meeting the fast changing needs of pharmaceutical companies with international operations. The Board of Directors expresses its thanks to Rudolf Hanko for his great achievements on behalf of the company and is glad he will remain closely connected with Siegfried».
Wolfgang Wienand (born 1972) joined Siegfried’s Executive Committee in 2010, and as Chief Scientific & Strategy Officer he is responsible for global research and development activities and for Strategy, Mergers & Acquisitions, Legal, IP Management and Regulatory Affairs. Andreas Casutt: «The Board of Directors is pleased to appoint the new CEO from within the company. Wolfgang Wienand has made a decisive contribution toward implementation of our corporate strategy by means of successful acquisitions in recent years. He demonstrated significant leadership qualities as the person responsible for overseeing the post-merger integration of the new corporate entities and as global head of Research and Development. Thus Wolfgang Wienand has all the prerequisites to lead our company as CEO into a successful future».
CV Dr. Rudolf Hanko
Rudolf Hanko (1955) was appointed CEO of Siegfried Group in May 2009. Prior to joining Siegfried, he worked in the chemical-pharmaceutical industry in various management positions, at Evonik Industries AG as Head of the Exclusive Synthesis and Amino Acids business. Prior to that, Rudolf Hanko also headed Chemical Research within the pharmaceutical division of Bayer AG and was General Manager of the fine chemicals division.
Rudolf Hanko received his Ph.D. in chemistry from the University of Göttingen and completed post-doctoral studies at the Max-Planck Institute.
Rudolf Hanko is a German citizen.
CV Dr. Wolfgang Wienand
As of August 1, 2010, Dr. Wolfgang Wienand (1972) was responsible for Siegfried’s global Research and Development activities. Since December 2011, he has been leading the departments Strategy, Mergers & Acquisitions, Legal and Intellectual Property Management and Regulatory Affairs. In May 2017, he took over responsibility for both areas. Before joining Siegfried, he held senior management positions at Evonik Industries AG with a focus on fine chemistry and custom manufacturing for the pharmaceutical industry.
Wolfgang Wienand studied chemistry at the University of Bonn and subsequently obtained a Ph.D. in organic and bioorganic chemistry from the University of Cologne. In addition, he holds an Executive Master’s Degree in International Finance of HEC in Paris.
Wolfgang Wienand is a German citizen.
Peter A. Gehler
Tel. +41 62 746 11 48
Mobile +41 79 416 41 16
Siegfried Holding AG
Untere Brühlstrasse 4
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2017, Siegfried reported annual sales of CHF 751 million and employs at the time being approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN). Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.